<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719888</url>
  </required_header>
  <id_info>
    <org_study_id>2010.00</org_study_id>
    <secondary_id>NCI-2010-00190</secondary_id>
    <secondary_id>2010</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG2807002</secondary_id>
    <nct_id>NCT00719888</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease</brief_title>
  <official_title>Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving an umbilical cord blood transplant together with&#xD;
      cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients&#xD;
      with hematologic disease. Giving chemotherapy, such as cyclophosphamide and fludarabine, and&#xD;
      TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and&#xD;
      abnormal cells and helps stop the patient's immune system from rejecting the donor's stem&#xD;
      cells. When the healthy stem cells from a donor are infused into the patient they may help&#xD;
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.&#xD;
      Sometimes the transplanted cells from a donor can make an immune response against the body's&#xD;
      normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this&#xD;
      from happening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive myeloablative conditioning comprising fludarabine intravenously (IV)&#xD;
      over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo&#xD;
      high-dose TBI twice daily (BID) on days -4 to -1. Patients then undergo single- or&#xD;
      double-unit UCBT on day 0.&#xD;
&#xD;
      ARM II: Patients receive myeloablative conditioning comprising fludarabine IV over 30-60&#xD;
      minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days&#xD;
      -5 and -4, and middle-intensity TBI once daily (QD) on days -2 and -1. Patients then undergo&#xD;
      single- or double-unit UCBT on day 0.&#xD;
&#xD;
      Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours,&#xD;
      then cyclosporine orally (PO) (if tolerated), on days -3 to 100 with taper on day 101.&#xD;
      Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if&#xD;
      tolerated) three times daily (TID) on days 8-30. Mycophenolate mofetil is tapered to BID on&#xD;
      day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks&#xD;
      beginning on day 45 (or 15 days after engraftment if engraftment occurred &gt; day 30) after&#xD;
      engraftment if there continues to be no evidence of acute GVHD.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 6 months, 1 year, and 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2005</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>A non-statistical comparison with historical controls will be made. Monitoring will take place separately for the single and double umbilical cord blood transplantation (UCBT) cohorts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in level of chimerism at multiple time points</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Cumulative incidence estimates will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transplant-related mortality</measure>
    <time_frame>At 6 months</time_frame>
    <description>Monitoring will take place separately for the single and double UCBT cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutrophil engraftment</measure>
    <time_frame>At day 42</time_frame>
    <description>Monitoring will take place separately for the single and double UCBT cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of platelet recovery</measure>
    <time_frame>At 6 months</time_frame>
    <description>Monitoring will take place separately for the single and double UCBT cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV and III-IV acute graft-versus-host disease (GVHD)</measure>
    <time_frame>At day 100</time_frame>
    <description>Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level. Monitoring will take place separately for the single and double UCBT cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant infections</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Monitoring will take place separately for the single and double UCBT cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cumulative incidence estimates will be used to summarize the time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>A non-statistical comparison with historical controls will be made. Cumulative incidence estimates will be used to summarize the time-to-event outcomes. Monitoring will take place separately for the single and double UCBT cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single unit umbilical cord blood (UCB) transplants with historical controls</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Single unit UCB transplants with historical controls will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single unit UCB transplants with double unit UCB transplants</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Single unit UCB transplants with double unit UCB transplants will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Refractory Anemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.&#xD;
Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred &gt; day 30) after engraftment if there continues to be no evidence of acute GVHD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single- or double-unit UCBT on day 0.&#xD;
Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred &gt; day 30) after engraftment if there continues to be no evidence of acute GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Double-Unit Umbilical Cord Blood Transplantation</intervention_name>
    <description>Undergo double-unit UCBT</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
    <other_name>118218</other_name>
    <other_name>Fluorovidarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo high-dose or moderate-intensity TBI</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>SCT_TBI</other_name>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Undergo UCBT</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <arm_group_label>Treatment (myeloablative UCBT)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (myeloablative UCBT)</arm_group_label>
    <other_name>1,1',1&quot;-phosphinothioylidynetrisaziridine</other_name>
    <other_name>1,1',1''-Phosphinothioyldynetrisaziridine</other_name>
    <other_name>52-24-4</other_name>
    <other_name>6396</other_name>
    <other_name>Girostan</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  GRAFT CRITERIA:&#xD;
&#xD;
               -  UCB units will be selected according to current umbilical cord blood graft&#xD;
                  selection algorithm; one or 2 UCB units may be used to achieve the required cell&#xD;
                  dose&#xD;
&#xD;
               -  The UCB graft is matched at 4-6 human leukocyte antigen (HLA)-A, B, DRB1 antigens&#xD;
                  with the recipient; this may include 0-2 antigen mismatches at the A or B or DRB1&#xD;
                  loci; unit selection based on cryopreserved nucleated cell dose and HLA-A,B, DRB1&#xD;
                  using intermediate resolution A, B antigen and DRB1 allele typing&#xD;
&#xD;
               -  If 2 UCB units are required to reach the target cell dose, each unit must be a&#xD;
                  4-6 antigen match to the recipient&#xD;
&#xD;
          -  Age and Disease Criteria:&#xD;
&#xD;
               -  High-dose TBI regimen: 6 months to =&lt; 45 years&#xD;
&#xD;
               -  Middle-intensity TBI regimen: 6 months to =&lt; 65 years&#xD;
&#xD;
               -  Conditioning regimen selection should be based on the underlying disease,&#xD;
                  presence of minimum residual disease (MRD), age, co-morbidities, and attending&#xD;
                  physician&#xD;
&#xD;
          -  Acute myeloid leukemia, including biphenotypic acute leukemia or mixed-lineage&#xD;
             leukemia:&#xD;
&#xD;
               -  All patients must be in complete remission (CR) as defined by hematologic&#xD;
                  recovery and &lt; 5% blasts by morphology/flow cytometry in a representative bone&#xD;
                  marrow sample with cellularity &gt;= 15% for age; patients who do not have high-risk&#xD;
                  features (for example preceding myelodysplastic syndrome [MDS], high-risk&#xD;
                  cytogenetics, &gt;= 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia&#xD;
                  or &gt;= CR2) must be discussed with the principal investigator (PI) prior to&#xD;
                  enrollment and at the Patient Care Conference or equivalent group such as the&#xD;
                  pediatric leukemia board as an alternative&#xD;
&#xD;
               -  Patients in whom adequate marrow/biopsy specimens cannot be obtained to determine&#xD;
                  remission status by morphologic assessment, but have fulfilled criteria of&#xD;
                  remission by flow cytometry, recovery of peripheral blood counts with no&#xD;
                  circulating blasts, and/or normal cytogenetics (if applicable) may still be&#xD;
                  eligible; reasonable attempts must be made to obtain an adequate specimen for&#xD;
                  morphologic assessment, including possible repeat procedures; these patients must&#xD;
                  be discussed with the PI prior to enrollment; patients persistently aplastic for&#xD;
                  greater than one month since completing last chemotherapy are also eligible with&#xD;
                  PI approval&#xD;
&#xD;
          -  Very high risk pediatric/young adult patients with acute myeloid leukemia (AML):&#xD;
             Patients =&lt; 25 years, however, are eligible with (M2 marrow) with =&lt; 25% blasts in&#xD;
             marrow after having failed one or more cycles of chemotherapy; this group of patients&#xD;
             will be analyzed separately&#xD;
&#xD;
          -  Acute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage&#xD;
             leukemia:&#xD;
&#xD;
               -  All patients must be in CR as defined by &lt; 5% blasts by morphology; flow&#xD;
                  cytometry in a representative bone marrow sample with cellularity &gt;= 15% for age;&#xD;
                  patients who do not have high-risk disease (high risk CR1, greater than one cycle&#xD;
                  to obtain CR or &gt;= CR2) must be discussed with the PI prior to enrollment and at&#xD;
                  the Patient Care Conference or equivalent group such as the pediatric leukemia&#xD;
                  board as an alternative&#xD;
&#xD;
               -  Patients in whom adequate marrow/biopsy specimens cannot be obtained to determine&#xD;
                  remission status by morphologic assessment, but have fulfilled criteria of&#xD;
                  remission by flow cytometry, recovery of peripheral blood counts with no&#xD;
                  circulating blasts, and/or normal cytogenetics (if applicable) may still be&#xD;
                  eligible; reasonable attempts must be made to obtain an adequate specimen for&#xD;
                  morphologic assessment, including possible repeat procedures; these patients must&#xD;
                  be discussed with the principal investigator Ann Dahlberg prior to enrollment;&#xD;
                  patients persistently aplastic for greater than one month since completing last&#xD;
                  chemotherapy are also eligible with PI approval&#xD;
&#xD;
          -  Chronic myelogenous leukemia excluding refractory blast crisis; to be eligible in&#xD;
             first chronic phase (CP1) patient must have failed or be intolerant to imatinib&#xD;
             mesylate&#xD;
&#xD;
          -  Advanced myelofibrosis&#xD;
&#xD;
          -  Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate&#xD;
             (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB], RAEB in&#xD;
             transformation [RAEBt]) or refractory anemia with severe pancytopenia or high risk&#xD;
             cytogenetics; blasts must be &lt; 10% by a representative bone marrow aspirate morphology&#xD;
&#xD;
          -  Lymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade non-Hodgkin lymphoma&#xD;
             (NHL) after initial therapy if stage III/IV in first partial response (PR1) or after&#xD;
             progression if stage I/II &lt; 1 year; stage III/IV patients are eligible after&#xD;
             progression in CR/PR&#xD;
&#xD;
          -  Chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL), marginal zone&#xD;
             B-cell lymphoma, lymphoplasmacytic lymphoma or follicular lymphoma that have&#xD;
             progressed after at least two different prior therapies; patients with bulky disease&#xD;
             (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before&#xD;
             transplant; these patients must be presented at primary care center (PCC) prior to&#xD;
             enrollment, given potential competing eligibility on autotransplant protocols&#xD;
&#xD;
          -  Mantle-cell lymphoma, prolymphocytic leukemia: Eligible after initial therapy in &gt;=&#xD;
             CR1 or &gt;= PR1&#xD;
&#xD;
          -  Large cell NHL &gt; CR2/&gt; second partial response (PR2):&#xD;
&#xD;
               -  Patients in CR2/PR2 with initial short remission (&lt; 6 months) are eligible&#xD;
&#xD;
               -  These patients must be presented at PCC prior to enrollment, given potential&#xD;
                  competing eligibility on autotransplant protocols&#xD;
&#xD;
          -  Multiple myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response&#xD;
             lasting less than 6 months, or beta-2 microglobulin &gt; 3 mg/L, may be considered for&#xD;
             this protocol after initial therapy&#xD;
&#xD;
          -  Performance status score: Karnofsky (for adults) &gt;= 70% or Eastern Cooperative&#xD;
             Oncology Group (ECOG) 0-1 or Lansky (for children) &gt;= 50%&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL (for adults) or creatinine clearance &gt; 60 ml/min (for children)&#xD;
&#xD;
          -  Patients with clinical or laboratory evidence of liver disease will be evaluated for&#xD;
             the cause of liver disease, its clinical severity in terms of liver function,&#xD;
             histology, and the degree of portal hypertension; patients with fulminant liver&#xD;
             failure, cirrhosis with evidence of portal hypertension or bridging fibrosis,&#xD;
             alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices,&#xD;
             hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by&#xD;
             prolongation of the prothrombin time, ascites related to portal hypertension,&#xD;
             bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total&#xD;
             serum bilirubin &gt; 3 mg/dL, and symptomatic biliary disease will be excluded&#xD;
&#xD;
          -  Diffusion capacity for carbon monoxide corrected (DLCOcorr) &gt; 50% normal or a&#xD;
             pediatric patient who is unable to perform pulmonary function tests (PFTs) but has&#xD;
             adequate pulmonary function&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 45% or shortening fraction &gt; 26%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled viral or bacterial infection at the time of study enrollment&#xD;
&#xD;
          -  Active or recent (prior 6 month) invasive fungal infection without interdisciplinary&#xD;
             (ID) consult and approval&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after&#xD;
             &gt; 2 salvage regimens)&#xD;
&#xD;
          -  Patients with history of prior myeloablative transplant containing full dose TBI&#xD;
             (greater than 8 gray [Gy]) will not be eligible for Regimen A; however, they may still&#xD;
             enroll on Regimen B if they otherwise meet inclusion and exclusion criteria&#xD;
&#xD;
          -  Any prior myeloablative transplant within the last 6 months&#xD;
&#xD;
          -  Patients &gt;= 45 years: comorbidity score of 5 or higher&#xD;
&#xD;
          -  Patients who have received Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as&#xD;
             part of their salvage therapy are not eligible for Regimen A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann E. Dahlberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann E. Dahlberg</last_name>
    <phone>206-667-1959</phone>
    <email>adahlber@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann E. Dahlberg</last_name>
      <phone>206-667-1959</phone>
      <email>adahlber@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Ann E. Dahlberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2008</study_first_submitted>
  <study_first_submitted_qc>July 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

